- Home
- MBVI vs VALN Comparison
MBVI vs VALN Comparison
Compare MBVI & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBVI | VALN |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 439.4M | 495.5M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MBVI | VALN |
|---|---|---|
| Price | $10.22 | $6.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 2.2K | ★ 77.9K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.99 | $4.75 |
| 52 Week High | $10.23 | $12.23 |
Technical Indicators
Market Signals| Indicator | MBVI | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 64.52 | 60.79 |
| Support Level | $9.99 | $5.03 |
| Resistance Level | N/A | $6.60 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 78.57 | 56.42 |
Price Performance
Historical ComparisonAbout MBVI M3-Brigade Acquisition VI Corp. Class A Ordinary Shares
M3-Brigade Acquisition VI Corp is a newly incorporated blank check company.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.